Avatrombopag medical insurance reimbursement policy

Avatrombopag (Avatrombopag) is used to treat thrombocytopenia (a lack of platelets in the blood) in adults with chronic liver disease who are scheduled to undergo medical procedures. Avatrombopag is also used to treat chronic immune thrombocytopenia when other treatments have failed. Avatrombopag does not cure thrombocytopenia and will not normalize your platelet count. Avatrombopag may also be used for purposes not listed in this Medication Guide, but only under the supervision of your doctor.

The original drug of avatrombopag has been marketed and sold in China under the name of avatrombopag maleate tablets, with the trade name Su Kexin, and has entered the scope of Class B medical insurance through the relevant regulations of the National Medical Insurance Administration. The current medical insurance reimbursement policy is limited to chronic patients who undergo elective diagnostic procedures or surgeries. Adult patients with liver disease-related thrombocytopenia are reimbursed by the national medical insurance. Patients who do not meet the conditions can only purchase this drug at their own expense. The reimbursement ratio is different in different urban areas, and the price after reimbursement may be different. Patients in need can consult the local medical insurance bureau or hospital.

The original version of avatrombopag marketed in China, with a common specification of 20mg*15 tablets, may cost more than RMB 7,000 per box, while the original version of avatrombopag sold overseas is even more expensive. It is understood that there are generic drugs of avatrombopag available overseas, and their pharmaceutical ingredients are basically the same as those of the original drug. For example, the price of a box of 20mg*30 tablets in Laos pharmaceutical production specifications may be around RMB 1,000 (the price may fluctuate due to exchange rates). For specific price and drug information of avatrombopag, please consult a medical consultant.